Highlights and Quick Summary
- Long Term Debt (Total) for the quarter ending June 30, 2023 was $448 Million (a 0.07% increase compared to previous quarter)
- Year-over-year quarterly Long Term Debt (Total) decreased by -56.59%
- Annual Long Term Debt (Total) for 2022 was $449 Million (a -44.59% decrease from previous year)
- Annual Long Term Debt (Total) for 2021 was $809 Million (a -3.76% decrease from previous year)
- Annual Long Term Debt (Total) for 2020 was $841 Million (a 5.34% increase from previous year)
Visit stockrow.com/EBS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Long Term Debt (Total) of Emergent Biosolutions Inc.
Most recent Long Term Debt (Total)of EBS including historical data for past 10 years.Interactive Chart of Long Term Debt (Total) of Emergent Biosolutions Inc.
Emergent Biosolutions Inc. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $448.0 | $447.7 | – | – | – |
| 2022 | $448.5 | $1,032.1 | $793.6 | $801.5 | $448.5 |
| 2021 | $809.4 | $817.3 | $825.2 | $833.1 | $809.4 |
| 2020 | $841.0 | $848.5 | $758.1 | $762.9 | $841.0 |
| 2019 | $798.4 | $813.3 | $830.4 | $732.4 | $798.4 |
| 2018 | $784.5 | $13.5 | $13.48 | $13.47 | $784.5 |
| 2017 | $13.5 | $248.99 | $248.69 | $248.39 | $13.5 |
| 2016 | $248.09 | $247.79 | $247.39 | $247.19 | $248.09 |
| 2015 | $246.89 | $253.0 | $253.0 | $251.0 | $246.89 |
| 2014 | $251.0 | $251.0 | $251.0 | $251.0 | $251.0 |
| 2013 | $62.0 | $54.95 | $56.07 | $57.19 | $62.0 |
| 2012 | $58.3 | $58.87 | – | – | $58.3 |
Business Profile of Emergent Biosolutions Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic